Use of Venlafaxine in the treatment of adult attention deficit hyperactivity disorder

The efficacy of Venlafaxine in comparison with placebo in the treatment of adult with attention deficit hyperactivity disorder: A double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138808122660N1

Enrollment

Registered

2010-01-25

Start date

2009-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult ADHD (Attention-deficit hyperactivity disorder ). Hyperkinetic disorders

Interventions

Intervention 1: Intervention group: Venlafaxine

weeks 1, 2

75mg/day (once daily), weeks 3, 4 150mg/day (twice daily) and weeks 5, 6

225mg/day (thrice daily). Intervention 2: Control group: placebo.

Treatment - Drugs

Placebo

Intervention group: Venlafaxine

225mg/day (thrice daily)

Control group: placebo

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age between 18-45 year 2. Having Adult attention deficit hyperactivity disorder (ADHD) according to the judgment of two psychiatrists 3. Confirm of ADHD symptoms at childhood period. Exclusion criteria: 1. Evidence of mental retardation ( IQ<70 based on clinical judgment ) 2. Other psychiatric comorbidity 3. Any significant chronic medical condition, including organic brain disorder and seizure 4. Current abuse or dependence on substance within 6 months 5. Pregnant and lactating women . 6. use any psychiatirc drugs in recent two weeks

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvement in Attention-deficit symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the self-report Conner's questionnaire.;Improvement in impulsivity. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.;Improvement in hyperactivity symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.	—

Measure

Time frame

Improvement in Attention-deficit symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the self-report Conner's questionnaire.;Improvement in impulsivity. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.;Improvement in hyperactivity symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahrokh Amiri Azizabad

Tabriz University Of Medical Sciences

Amirish@tbzmed.ac.ir , Sh_Amiri1348@yahoo.com+98 411380448690

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026